Loading company…
Vittoria Biotherapeutics develops cell therapy and gene editing technologies, including CAR T cell treatments.
Founded in 2021 and based in Pennsylvania, US, Vittoria Biotherapeutics develops cell therapies and gene editing technologies. Its Senza5 platform combines genetic engineering with a five-day manufacturing process, with a focus on T cell and CAR T cell therapies. In June 2022, the company raised USD 10 million in seed funding from Agent Capital and Tellus BioVentures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in